Clinical Trials Cultivation DEA Law 
NORML
OCTOBER 21, 2019
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.
The Cannigma
JUNE 14, 2021
For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis. BRC) told The Cannigma this week.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
APRIL 12, 2022
Attorneys representing a cannabis biopharma conglomerate and federal cannabis cultivation license applicant filed a petition in court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application. . Breaking Exclusive: Another Cannabis Company Sues the DEA. Read more at.
WeedAdvisor
JULY 4, 2019
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.
Cannabis Law Report
NOVEMBER 4, 2021
Drug Enforcement Agency (DEA) to cultivate marijuana for research purposes. The DEA dragged their feet on this plan for years, so lawsuits were filed. delta-9 THC, meaning they aren’t a controlled substance under federal law. Use the plants for their own studies and/or FDA clinical trials.
Cannabis Law Report
MARCH 30, 2022
Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. The full text of S. 253 is online here.
NORML
MARCH 1, 2019
” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue. .”
Expert insights. Personalized for you.
103 
Let's personalize your content